GT Biopharma (NASDAQ:GTBP) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

GT Biopharma (NASDAQ:GTBP) released its earnings results on Friday. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03), FiscalAI reports.

GT Biopharma Price Performance

GT Biopharma stock traded down $0.05 during trading hours on Friday, reaching $0.39. The stock had a trading volume of 3,999,203 shares, compared to its average volume of 1,197,280. The stock has a market cap of $14.03 million, a PE ratio of -0.06 and a beta of 0.64. GT Biopharma has a 52 week low of $0.26 and a 52 week high of $3.85. The company has a fifty day simple moving average of $0.40 and a 200-day simple moving average of $0.57.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GT Biopharma in a report on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, GT Biopharma has an average rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).